1. Home
  2. SLN vs AOD Comparison

SLN vs AOD Comparison

Compare SLN & AOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • AOD
  • Stock Information
  • Founded
  • SLN 1994
  • AOD 2006
  • Country
  • SLN United Kingdom
  • AOD United States
  • Employees
  • SLN N/A
  • AOD N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • AOD Investment Managers
  • Sector
  • SLN Health Care
  • AOD Finance
  • Exchange
  • SLN Nasdaq
  • AOD Nasdaq
  • Market Cap
  • SLN 842.4M
  • AOD 903.5M
  • IPO Year
  • SLN N/A
  • AOD N/A
  • Fundamental
  • Price
  • SLN $12.70
  • AOD $8.69
  • Analyst Decision
  • SLN Strong Buy
  • AOD
  • Analyst Count
  • SLN 4
  • AOD 0
  • Target Price
  • SLN $61.50
  • AOD N/A
  • AVG Volume (30 Days)
  • SLN 184.3K
  • AOD 301.9K
  • Earning Date
  • SLN 11-14-2024
  • AOD 01-01-0001
  • Dividend Yield
  • SLN N/A
  • AOD 8.43%
  • EPS Growth
  • SLN N/A
  • AOD N/A
  • EPS
  • SLN N/A
  • AOD N/A
  • Revenue
  • SLN $21,773,221.00
  • AOD N/A
  • Revenue This Year
  • SLN N/A
  • AOD N/A
  • Revenue Next Year
  • SLN $104.98
  • AOD N/A
  • P/E Ratio
  • SLN N/A
  • AOD N/A
  • Revenue Growth
  • SLN N/A
  • AOD N/A
  • 52 Week Low
  • SLN $8.94
  • AOD $7.02
  • 52 Week High
  • SLN $27.72
  • AOD $8.45
  • Technical
  • Relative Strength Index (RSI)
  • SLN 15.31
  • AOD 36.51
  • Support Level
  • SLN $17.11
  • AOD $8.71
  • Resistance Level
  • SLN $18.24
  • AOD $8.95
  • Average True Range (ATR)
  • SLN 0.89
  • AOD 0.09
  • MACD
  • SLN -0.49
  • AOD -0.01
  • Stochastic Oscillator
  • SLN 1.06
  • AOD 10.34

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest

Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. It predominantly invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, Industrials among other sectors.

Share on Social Networks: